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ABSTRACT
Background: Estimating the cumulative prevalence of SARS-COV-2 will help to
understand the epidemic, contagion, and immunity to COVID-19 in vulnerable
populations. The objective is to determine the extent of infection in the general
population and the cumulative incidence by age group.
Methods: It was carried out with a longitudinal analytical study, in the population of
the Lambayeque region, located in the north of Peru. The selection was carried out in
multistages (districts, area, household, and finally choosing the interviewee within
the house). Seroprevalence was estimated as a positive result of the rapid test whether
it was positive IgM or positive IgG. An adjustment was made for the sampling
weights used.
Results: The seroprevalence found in the region was 29.5%. Young people between
21 and 50 years old presented the highest seroprevalence frequencies. A total of
25.4% were asymptomatic. The most frequent complaint was dysgeusia and
dysosmia (85.3% and 83.6%). Dysosmia (PR = 1.69), chest pain (PR = 1.49),
back pain (PR = 1.45), cough (PR = 1.44), fever (PR = 1.41), general malaise
(PR = 1.27) were associated factors with the higher the frequency of seropositivity for
SARS-CoV-2. Reporting of complete isolation at home decreased the frequency of
positivity (PR = 0.80), however, reporting having ARI contact (PR = 1.60), having
contact with a confirmed case (PR = 1.51), and going to market (PR = 1.26) increased
the frequency of positivity for SARS-CoV-2.
Conclusion: These results suggest that Lambayeque is the region with the highest
seroprevalence in the world, well above Spain, the United States and similar to a
study in India.
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INTRODUCTION
On January 30, 2020, the World Health Organization (WHO) declared coronavirus
infection 2019 (COVID-19) as a public health emergency of international concern (World
Health Organization, 2020). To date, nearly 90 million confirmed COVID-19 cases
have been reported (Worldometeres). In Peru, the pandemic began on March 6, 2020,
since then almost 471 thousand cases have been reported, of which 88.7% are mild and
asymptomatic (Ministry of Health of Peru (MINSA), 2020).
Previous studies have found that 80.9% of COVID-19 cases have mild disease (Hu et al.,
2020) and 40–45% are asymptomatic (Oran & Topol, 2020) with different clinical
courses due to the heterogeneity of the affected population. Asymptomatic cases with
COVID-19 have shown active subclinical infection, managing to transmit the virus to
other people for a prolonged period (more than 14 days), its identification and
characterization being crucial to control outbreaks in various regions (Hu et al., 2020;
Oran & Topol, 2020).
For the detection of SARS-CoV-2, the IgM and IgG antibodies produced from the
second week of viral infection are used (Sethuraman, Jeremiah & Ryo, 2020), which detect
antibodies against the nucleocapsid antigen and have an immunological memory for up
to 6 weeks after being transmitted from person to person (Li et al., 2005; Tan et al., 2020).
The use of rapid tests has a false positive rate that is less than 3% (Lisboa Bastos et al.,
2020).
This is useful in the development of epidemiological studies, where it is required to
evaluate the presence of antibodies (IgM or IgG) to know the accumulated prevalence of
cases with COVID-19 infection.
Currently, in Peru, the diagnosis of COVID-19 is limited to examining patients who
require medical attention for symptoms, or contact of those confirmed patients, which
in addition to affecting the presentation of the national and local epidemic curves
(Loyola et al., 2020) underestimates the real number of patients with asymptomatic or
subclinical COVID-19. Estimating the cumulative prevalence of SARS-COV-2 will help to
understand the epidemiology of the outbreak, contagion, and immunity to COVID-19 in
vulnerable populations (Munster et al., 2020), as well as to know the proportion of the
population that has already developed antibodies to anticipate its dynamics and plan a
public health response appropriately (Clapham et al., 2020; Lipsitch, Swerdlow & Finelli,
2020).
In this work, a population epidemiological investigation is presented at the Lambayeque
region level, through a serological evaluation whose objective is to determine the extent
of the infection in the general population and the cumulative incidence by age group, as
well as to determine the proportion of asymptomatic infections or subclinical.
MATERIALS AND METHODS
Study design and participants
The seroprevalence study was carried out with a prospective, analytical cross-sectional
study design of population inference at the level of the Lambayeque region, a region
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located in the North of Peru. Lambayeque has a total population of 1,197,260 inhabitants
and is divided into three provinces. The population has 48.5% males; of the total
population, the population aged 15–64 represents 64% and those over 65 represent
8.8%. The age distribution by sex tends to be similar in both groups (National Institute of
Statistics and Informatics of Peru (INEI), 2018).
Sample and sampling
To calculate the sample size, the population size of 1,197,260 inhabitants was taken as a
reference (Informática INdEe, 2018). The expected proportion of seropositivity in the
population of 4.5% (Sood et al., 2020) was considered, with a confidence level of 95%
and an absolute precision of 0.01 and at the level of three provinces Chiclayo, Ferreñafe,
and Lambayeque, stratified by sex, giving a total of 2,010 people. Due to the dynamic
condition of the population, it was optimized for its forecast at the date of application of
the sampling with the application of simple linear regression analysis and the logarithm
growth method.
The selection was carried out in multistages, the first stage was carried out in 38 districts,
selected with probabilities proportional to their population size, then random samples
were taken from the area, from the group of each area and household selection within the
group, finally choosing the interviewee inside the house. People who had previously
had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded.
The selection of a home was made, taking into account the next home at a distance
of no less than 50 m and no more than five homes per block.
At the level of each of the selected households in each district, the following inclusion
criteria were considered for the evaluation: person should be over 9 years of age and reside
in the household for more than 21 days. Institutional places (residents of nursing
homes, residential complexes, persons deprived of liberty, hospitalized persons, convents,
and shelters) and health personnel who have worked in a healthcare center in the previous
30 days were excluded.
For the selection of the person, the Kish method was used, which consists of ordering all
members of the family from the youngest to oldest, and then making a random selection
through an electronic generator without repetition.
SARS-Cov-2 antibody detection
The positivity of the antibodies against SARS-CoV-2 was determined by the lateral
flow test (LFIA, Lateral Flow Immunoassay). “Coretest COVID-19 IgM/IgG Ab Test”
from Core Technology, which uses the principle based on nano-colloidal technology,
the application of a highly specific antigen-antibody reaction, and the principle of
immunochromatographic analysis. The seropositivity in the present study is based on
the qualitative detection of positive IgM, IgG, or IgM/IgG antibodies in all cases.
The tests were carried out using the brand protocol; the fingertip was pierced with a
disposable lancet, collecting the blood with a pipette. Ten uL of whole blood plus two drops
of detection buffer were added to the cassette, the results being read at 15 min.
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Procedures
The patient selection date was from June 24 2020 to July 10 2020. The fieldwork was
carried out by trained health personnel, all under a strict selection and sampling protocol,
as well as the correct application and interpretation of the test.
The selected participants were invited to participate in the study, after they accepted the
epidemiological file elaborated by the Ministry of Health of Peru was applied, this file
collects epidemiological data (age, sex, isolation, contact with a suspicious person or
confirmed for SARS-CoV-2), clinical data (fever, cough, chills, sore throat, malaise,
shortness of breath, headache, anosmia or ageusia, dysosmia, vomiting, diarrhea) as well as
the presence of comorbidities (hypertension, diabetes, obesity, bronchial asthma, cancer,
tuberculosis, COPD, etc.). The rapid test was taken at home, taking the appropriate
biosecurity measures. The responses to the questionnaire and the test results were recorded
on a website through a mobile application.
Statistical analysis
Seroprevalence was estimated as the proportion of participants who had a positive
rapid test result, whether IgM positive or IgG positive or IgM/IgG positive. An adjustment
was made for the sampling weights used, having seroprevalence estimates for different
selection probabilities. The sampling weights were calculated as the inverse of the
probability of sampling selection within the size of each stratum.
Due to the complex design of the selection, it was taken into account that all
statistical analyzes took into account the calculated weights, and this was carried out by
analyzing with svyset in the statistical package Stata v16.0 (StataCorp, College Station,
TX, USA).
For the descriptive analysis, frequencies and percentages were estimated for categorical
variables, and for numerical variables, the type of distribution was evaluated according to
the histogram and evaluation of bias and kurtosis, being summarized in measures of
central tendency and dispersion.
The bivariate analysis was carried out to know the relationship of factors to
SARS-CoV-2 seropositivity, applying the chi-square test when the dependent variable
was categorical, or with Student’s T or Mann–Withney tests according to the distribution
of the numeric variable.
Regression analysis was performed using generalized linear models, estimating
prevalence ratios (PR) utilizing Poisson family and logarithm link, estimating 95%
confidence intervals (95% CI) and p-values.
In addition, a correction was made for the prevalence of the disease due to the use of an
inaccurate test (Sensitivity: 66% and specificity 97%) (Lisboa Bastos et al., 2020), using
Bayesian estimation and the calculation of confidence intervals with Bootstrap.
Ethical aspects
The research protocol was approved by the ethics committee of the Almanzor Aguinaga
Asenjo Hospital (registration number 042-2020).
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The people who were selected were explained the objective of the research, as well as the
risks and benefits of the study. Written informed consent was obtained from all study
participants. Consent for adults was used, as well as the consent and assent of children and
adolescents, children under 9 years of age was not taken into the protocol so as not to
violate their autonomy. Positive cases were notified to the coordinator for the application
of outpatient management.
RESULTS
Of the 2010 people surveyed, and estimated calculations by complex sampling, the
seroprevalence at the regional level in Lambayeque of SARS-CoV-2 was 29.5% (95% CI
[27.6–31.5]), and this was similar to the three provinces. See Table 1. The distribution of
seroprevalences by district varied, reaching seroprevalences of 60% (See Fig. 1). After
weighing the data by diagnostic performance, a prevalence of 42.15% was obtained (95%
CI [38.17–46.51]).
The seroprevalence was similar in men and women (30.1% and 28.8% respectively).
The age group from 31 to 40 years old presented the highest number of positive patients
with 34.9%, this being lower in those older than 61 years and older, where it can be seen
that seroprevalence decreased.
The presence of symptoms related to COVID-19 was reported by 22.8% of people,
however, of them, only 43.5% gave a positive result. One in four asymptomatic people
tested positive for SARS-CoV-2. Only 810 (41.4%) people complied with strict isolation in
the region, and 25.8% of them were seropositive, as opposed to 32.2% of those who did not
comply with strict isolation. See Table 1.
Of the patients with positive infection, symptoms, and signs the most frequent were
dysgeusia (85.3%), dysosmia (83.6%), and diarrhea (60.5%). While those who had a
negative result for SARS-CoV-2, the most frequent were irritability/confusion (30%),
abdominal pain (29.3%), and nausea/vomiting (29.2%). See Fig. 2.
In the bivariate analysis, multiple symptoms and signs were associated with positivity
for SARS-CoV-2, however, in the multivariate analysis, people who reported fever (PR:
1.41), general malaise (PR: 1.27), cough (PR: 1.44), dysosmia (PR: 1.69), chest pain
(PR: 1.49) and back pain (PR: 1.45) were associated with a higher frequency of positivity.
In the analysis of comorbidities, no comorbidity was associated with positivity for
SARS-CoV-2.
Of the behaviors, those who reported complying with strict home isolation had 20% less
frequency of testing positive for SARS-CoV-2 (PR = 0.80). However, having contact
with patients with acute respiratory infection (ARI), contact with a confirmed case in the
last 14 days, and going to the market, the frequency of testing positive was 60% (PR = 1.60),
51% (PR = 1.51 ) and 26% (PR = 1.26) higher; respectively. See Table 2.
DISCUSSION
Principal findings
Our study found that the seroprevalence of SARS-CoV-2 in the region of Lambayeque,
Peru was 29.6%, where the province with the highest prevalence of the virus was
Díaz-Vélez et al. (2021), PeerJ, DOI 10.7717/peerj.11210 5/16
Table 1 General characteristics and prevalence of SARS-CoV-2 in Lambayeque.
Variable n (2010) %* Prevalence* (IgM/IgG +) CI 95%*
Province 29.5 [27.6–31.5]
Lambayeque 476 23.6 32.9 [28.7–37.1]
Ferreñafe 163 8.3 22.5 [16.8–29.5]
Chiclayo 1,371 68.1 29.2 [26.9–31.6]
District
<20,000 hab. 538 28.9 23.0% [19.6–26.7]
20,000–50,000 hab. 469 25.6 32.7% [28.7–37.0]
>50,000 hab. 1,003 45.6 31.8% [29.0–34.8]
Age group
9–20 years 220 11.1 26.9% [21.4–33.2]
21–30 years 329 16.3 31.0% [26.1–36.1]
31–40 years 394 19.5 34.9% [30.3–39.8]
41–50 years 353 17.5 31.1% [26.5–36.2]
51–60 years 315 15.7 29.8% [25.0–35.1]
61–70 years 215 10.7 24.6% [19.2–30.8]
71–80 years 129 6.4 20.3% [14.2–28.2]
>80 years 55 2.7 22.1% [13.0–35.1]
Sex
Masculine 949 52.7 30.1% [27.4–33.0]
Femenine 1,061 47.3 28.8% [26.0–31.8]
Symptomatic
Yes 440 22.8 43.6% [38.9–48.3]
No 1,570 77.2 25.4% [23.3–27.5]
Isolation
Yes 810 41.4 25.8% [22.8–28.9]
No 1,200 58.6 32.2% [29.6–34.8]
Time of illness
≤14 days 239 55.2 33.3% [27.5–39.6]
>14 days 201 44.8 56.2% [49.2–63.0]
A previous visit to healthcare facility
Yes 67 3.4 39.1% [28.1–51.3]
No 1,943 96.6 29.2% [27.2–31.2]
Contact with ARI case
Yes 123 5.9 57.2% [48.2–65.7]
No 1,887 94.1 27.8% [25.8–29.8]
Contact with a confirmed case
Yes 142 7.2 52.3% [44.0–60.5]
No 1,868 92.8 27.7% [25.8–29.8]
Visit a market
Yes 442 21.1 38.0% [33.6–42.6]
No 1,568 78.9 27.1% [25.1–29.5]
Co-morbidity
Yes 450 22.3 27.4% [23.4–31.7]
No 1,560 77.7 30.3% [27.9–32.4]
Note:
* Estimates obtained by complex sampling. Strata were district.
Díaz-Vélez et al. (2021), PeerJ, DOI 10.7717/peerj.11210 6/16
Lambayeque (31.7%), followed by Chiclayo (29.8%). 28.1% presented an active infection.
Almost one in five patients was asymptomatic (25.7%) and the most frequently reported
symptoms were cough (29.7%), headache (29.4%), and sore throat (26.1%).
Additionally, we also explored the epidemiological clinical factors related to the
seroprevalence of SARS-CoV-2. The epidemiological factors associated with a higher
seroprevalence of SARS-CoV-2 were reported having had contact with a person with ARI,
Figure 1 Geospatial distribution of seroprevalence of SARS-CoV-2 in Lambayeque, Peru. Estimates
obtained by complex sampling. Strata were district. Full-size DOI: 10.7717/peerj.11210/fig-1
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contact with a confirmed case, and having visited a market 14 days before taking a sample
to detect the virus. Regarding clinical factors, it was found that people who reported
fever, general malaise, cough, dysosmia, abdominal pain, chest pain, and back pain had a
higher seroprevalence of SARS-CoV-2.
Seroprevalence of SARS-CoV-2
The SARS-CoV-2 seroprevalence study in the Lambayeque region, Peru showed that
29.6% (95% CI [27.5–31.6]) of the population present anti-SARS-CoV-2 antibodies, and
it is estimated that 354,389 infected people. This is higher than the official report of the
epidemiological situation reported during the investigation period (1,197,260 habitants;
Figure 2 Characteristics according to SARS-CoV-2 positivity in Lambayeque, Peru. COPD: Chronic
obstructive pulmonary disease. ARI: Acute respiratory infection. Estimates obtained by complex sam-
pling. Strata were district. (A) Signs and symptoms according to infection by SARS-CoV-2.
(B) Comorbilities according to infection by SARS-CoV-2. (C) Behaviour according to infection by
SARS-CoV-2. Blue percent with positives. Red percent without SARS-CoV-2.
Full-size DOI: 10.7717/peerj.11210/fig-2
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Table 2 Characteristics associated with seropositivity for SARS-CoV-2 in Lambayeque, Peru.
Characteristics PRc CI 95% PR(a) CI 95% with p-values
Signs/symptoms Model I
Fever/chills 2.21 [1.89–2.59] 1.41 [1.09–1.82] p = 0.008
General malaise 2.02 [1.71–2.38] 1.28 [0.99–1.65] p = 0.059
Cough 1.87 [1.59–2.20] 1.44 [1.16–1.78] p = 0.001
Sore throat 1.40 [1.15–1.72] 0.92 [0.73–1.18] p = 0.511
Nasal congestion 1.59 [1.26–2.09] 1.05 [0.80–1.38] p = 0.728
Shortness of breath 1.83 [1.36–2.45] 0.83 [0.57–1.21] p = 0.340
Diarrhea 2.10 [1.62–2.71] 1.12 [0.83–1.53] p = 0.439
Nausea/vomiting 1.99 [1.39–2.85] 1.16 [0.74–1.80] p = 0.537
Headache 1.43 [1.17–1.74] 0.89 [0.71–1.12] p = 0.339
Irritability/confusion 0.83 [0.35–1.98] 0.40 [0.20–0.79] p = 0.009
Dysosmia 2.92 [2.45–3.46] 1.69 [1.15–2.48] p = 0.007
Dysgeusia 2.96 [2.49–3.52] 1.22 [0.84–1.78] p = 0.304
Muscle pain 1.56 [1.18–2.08] 1.02 [0.76–1.39] p = 0.880
Abdominal pain 1.71 [1.07–2.74] 1.14 [0.70–1.83] p = 0.602
Chest pain 2.02 [1.54–2.64] 1.49 [1.09–2.05] p = 0.014
Backache 1.89 [1.41–2.53] 1.45 [1.05–1.99] p = 0.022
Co-morbility Model II
Pregnancy 1.28 [0.73–2.22] 1.25 [0.72–2.17] p = 0.429
Hypertension 0.83 [0.62–1.11] 0.84 [0.62–1.13] p = 0.246
Diabetes 0.90 [0.65–1.26] 0.93 [0.66–1.30] p = 0.663
Liver disease 0.53 [0.15–1.89] 0.55 [0.16–1.92] p = 0.344
Renal disease 1.18 [0.69–2.02] 1.19 [0.69–2.03] p = 0.533
COPD 0.62 [0.28–1.37] 0.63 [0.28–1.39] p = 0.930
Cancer 1.01 [0.44–2.30] 1.04 [0.45–2.40] p = 0.250
Obesity 0.97 [0.75–1.24] 0.96 [0.75–1.24] p = 0.770
Behavior Model III
Isolation 0.80 [0.69–0.93] 0.80 [0.69–0.92] p = 0.273
Travel* 0.98 [0.68–1.42] 0.79 [0.54–1.16] p = 0.472
Been in healthcare facility* 1.34 [0.98–1.83] 1.12 [0.80–1.55] p = 0.000
Contact with ARI* 2.06 [1.74–2.44] 1.60 [1.27–2.00] p = 0.001
Contact with confirmed case (14 previous days) 1.88 [1.58–2.25] 1.51 [1.21–1.89] p = 0.001
Been to market* 1.40 [1.21–1.61] 1.26 [1.09–1.46] p = 0.001
Notes:
* In the 14 days before taking the sample.
ARI: Acute respiratory infection. COPD: Chronic obstructive pulmonary disease.
Estimation carried out by complex samplings, prevalence ratios obtained with generalized linear models with Poisson
family, and logarithmic link. PR: Prevalence ratio. C: raw, a: adjusted. CI: Confidence interval.
Model I: Number of strata = 38; Number of PSUs = 2,010; Degree of freedom (df) = 1,972; F(16,1957) = 22.59; Prob >
F = 0.000.
Model II: Number of strata = 38; Number of PSUs = 2,010; Degree of freedom (df) = 1,972; F(8,1965) = 0.65; Prob >
F = 0.7316.
Model III: Number of strata = 38; Number of PSUs = 2,010; Degree of freedom (df) = 1,972; F(5,1968) = 20.02; Prob >
F = 0.0000.
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1.1% positivity; 14,355 infected people; 5,986 dead, source: Lambayeque epidemiological
room July 10, 2020). The infection fatality ratio calculated was 0.5%.
This finding, to our knowledge, suggests that the Lambayeque region represents the
highest seroprevalence of SARS-CoV-2. To date, the closest to this seroprevalence is in
Delhi, India (23.48%) (Ministry of Health and Family Welfare of India, 2020) where
they evaluated from June 27 to July 10, 2020, and only considered the prevalence of
positive IgG. Other studies indicate lower seroprevalences such as Madrid-Spain (11.3%,
95% CI [9.8–13]) (Pollán et al., 2020), Geneva-Switzerland (4.8%, 95% CI [2.4–8.0] to
10.8%, 95% CI [8.2–13.9]) (Stringhini et al., 2020), France (6.7%, 95% CI [5.36–8.11]),
Los Angeles-California (4.65%, 95% CI [2.52–7.07]) (Sood et al., 2020), China (3.2–3.8%)
(Xu et al., 2020), Italy (2.5%, 95% CI [2.3–2.6]), Georgia, USA (2.5%; 95% CI [1.4–4.45])
(Biggs et al., 2020), Indiana, USA (1.1%, 95% CI [0.76–2.54]) (Menachemi et al., 2020).
Technical reports of seroprevalence studies led by Regional Health Directorates
(DIRESA), still without being published in scientific publications, affirm figures lower
than those found in Lambayeque: Lima, Peruvian capital (24.3%, 95% CI [18.5–24.3]),
Cusco, southern Peruvian region (2.65%, 95% CI [1.23–4.07]). However, in Iquitos, a
seroprevalence of 71% was found (95% CI [68.0–74.7]). The differences found between
the estimates of the regions evaluated could be due to the date of the research (peaks
between regions), differences in the sample size and type of sampling used, among others.
It should be mentioned that all of these Peruvian seroprevalence studies for the detection
of SARS-CoV-2 used the rapid immunochromatography test.
The high seroprevalence reported in our research could be due to the identification
of epidemiological factors in the population of our study that condition high
transmissibility of the virus in the region. This is because 58.6% reported that they
have not maintained the mandatory social isolation measures (isolation PR: 0.80) and
21.1% have visited the market 14 days prior to the investigation (PR: 1.40), and this
conditions high transmissibility of the virus in the region. An investigation in Peru found
that the frequency of COVID-19 in market workers ranged from 20% to 90%, so these
places were areas of contagion in Lambayeque (Iglesias-Osores, Saavedra-Camacho &
Córdova-Rojas, 2020). Another factor that could explain the differences found is the
method used to detect antibodies against SARS-CoV-2, which has lower sensitivity in
contrast to ELISA or chemiluminescence tests (Lisboa Bastos et al., 2020). Our study used
the immunochromatography method, in contrast to that reported in India, the United
States, and Switzerland, where antibodies were measured with ELISA and in Italy (ELISA
and/or chemiluminescence-CLIA).
Regarding the seroprevalence reported in the districts of Lambayeque, we found a
geographic variability in the estimates. The districts of Picsi, Zaña, Kañaris, Incahuasi,
Chochope presented a seroprevalence of less than 10%. On the other hand, seroprevalences
higher than 50% were estimated in the districts of Pucalá and Mórrope. The geographic
variability found in our study is consistent with that reported in the United States
(Havers et al., 2020), where the seroprevalence range fluctuated between 1% and 6.9%.
This could be due to the great geographic variability that exists in Lambayeque since
each district has different overcrowding, behavior before the disease and level of
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development; it may also be because some conglomerates have probably respected the
social isolation measures decreed by the government during the state of emergency,
which would result in lower transmissibility of the virus in those districts. By Peruvian
regulations, all inhabitants when leaving their house had to wear a mask and have physical
distance from other people. It is necessary to mention the geographical point in which
the Lambayeque region is located, which is an intermediate point in Peruvian territory
with close access to multiple areas of the coast, mountains, and jungle; which results in a
very active formal and informal economic activity, as well as an easy point of entry
for probable asymptomatic or symptomatic residents of COVID-19. Finally, the high
prevalence could be because this region was severely hit by the high transmissibility of the
virus that caused the near sanitary collapse at the highest peak of the SARS-CoV-2
infection.
The estimated prevalence against SARS-CoV-2 was similar between both sexes
(men: 29.2%; women: 30.0%). This is consistent with what is described in the technical
reports made in our country (Lima and Cusco) and the population findings in Spain, the
United States (Havers et al., 2020; Pollán et al., 2020). However, it differs from what
was reported in Iquitos, where 73% and 58% of women and men had antibodies against
SARS-CoV-2s, respectively, this difference could be due to the fact that, in Iquitos, the
proportion of women and men is 4:3.
Epidemiological factors associated with the seroprevalence of
SARS-CoV-2
We found that people who reported respecting home isolation had a lower SARS-CoV-2
seroprevalence compared to those who mentioned having left their home during the
health emergency period. This is consistent with what has been evidenced in studies
conducted in Europe (Kuitunen et al., 2020;Martínez-Valero, Miranda &Martín-Sánchez,
2020). This could be explained by the fact that the effect of isolation and physical distance
slows down the transmission of the disease, especially this viral disease that is easily
transmissible. A recent review found that physical isolation measures and the use of
masks are effective in reducing the transmission of the disease (Chu et al., 2020).
While reporting has been in contact with a person with ARI and a confirmed
COVID-19 case 2 weeks before participation in this research was associated with a higher
prevalence of SARS-CoV-2 seroprevalence. This has been corroborated in a study that
evaluated close contacts who lived together with patients infected with SARS-CoV-2, who
had up to six times the risk of contracting the disease compared to other not so close cases
(Bi et al., 2020).
Likewise, going to a market 2 weeks before taking a sample for detection of
SARS-CoV-2 represented a higher seroprevalence of SARS-CoV-2. In our search for
information, we only found one study conducted in Baodi, China where 75.5% of its
confirmed cases had gone to markets (Wu et al., 2020). The probable explanation is
that the markets that exist in Lambayeque have not had a strict control to monitor
compliance with biosafety protocols, reduce their capacity, and it was unknown whether
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workers and/or buyers were infected, thus that would increase the possibility of
transmission as has been explained.
Clinical factors associated with SARS-CoV-2 seroprevalence
Participants who reported chest pain, back pain, fever, malaise, and cough were associated
with higher SARS-CoV-2 seroprevalence. This is similar to that reported in other studies
on factors related to virus positivity (Hu et al., 2020; Li et al., 2020), it should be noted
that, unlike other studies where fever and cough are the most frequent symptoms
(88.5% and 68.5% respectively (Li et al., 2020)), our study found that the most frequent
symptoms were cough and headache (29.7% and 29.4% respectively). This very marked
difference may be because the studies where information on signs and symptoms is
available are from hospital studies, unlike this study that was carried out at the community
level.
Implications of the findings
This research provides consistent scientific evidence for improving health decision-making
aimed at mitigating the impact of the COVID-19 pandemic in the Lambayeque region.
These findings represent the baseline measurement that will subsequently make it possible
to know the proportion of participants negative for SARS-CoV-2 who acquire active
disease infection, after completing the clinical follow-up. Additionally, it allows
addressing the frequency of asymptomatic cases and subsequently identifying the
presentation of symptoms throughout the clinical follow-up. These findings will also
make it possible to focus efforts on the districts with the highest proportion of
seroprevalence (epidemiological fences, traceability of cases and contacts at the
community level, targeted mandatory social quarantine measures, reinforcement, and
expansion of the first level of care and rapid response teams, among others).
Limitations and strengths
Our research has some limitations. First, it was not possible to use the immunoassay or
immunochemiluminesence diagnostic method to determine IgG antibodies, given its
better diagnostic precision, so the real estimate may have been much higher, as reported in
the correction with a Bayesian sample. Second, the seroprevalence found represents
only one Peruvian region, a country characterized by having multiple epidemics due to
its wide geographic diversity; however, these results may be representative since an
estimation has been made with complex multistage sampling and stratified by sex.
Third, there is a certain information bias in the estimates of factors associated with
seroprevalence, since it has not been possible to explore other characteristics that influence
the high transmissibility of the virus (economic level, educational level, overcrowding, and
basic services in housing, among others) with which may be an underestimation of the
measured factors, and there may be other unmeasured factors. Fourth, the actual
seroprevalence may be underestimated as repeated antibody measurements could not be
performed at different time points. Fifth, a double serological test was not performed to
differentiate a true and false positive; however, an attempt has been made to control the
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error in the test, so a Bayesian analysis was added to the results. Sixth, by not including
children less than 9 years of age, the study may not be representative of the entire
population. However, to our knowledge, this research represents one of the first population
seroepidemiological studies with a longitudinal design, even at the Latin American level,
characterized by a rigorous methodological implementation to conduct the research,
particularly in aspects of sampling, quality of information collection by government-
trained rapid response teams, sampling and biostatistical processing.
CONCLUSIONS
This research suggests that almost one in three people residing in the Lambayeque region,
Peru have antibodies against SARS-CoV-2. While having contact with a person with
ARI, contact with a confirmed case, going to a market the previous 14 days, presenting
general discomfort, cough, dysosmia, abdominal pain, chest pain, back pain could be
related to a greater seroprevalence of SARS-CoV-2.
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